Department of Health and Human Services$1.1M obligationsEnds Dec 18, 2021
Federal contract award
HHSN27500005
IGF::OT::IGF EVALUATION OF THE PHARMACOKINETIC PROFILE, EFFECTS ON THE MECHANISMS OF CONTRACEPTIVE EFFICACY AND SAFETY OF MULTIPURPOSE PREVENTION TECHNOLOGIES PRODUCTS
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | NATIONAL INSTITUTES OF HEALTH NICHD |
| NAICS | 541712 |
| PSC | AN12 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH |
| Parent award / vehicle | HHSN275201200002I |
| Set-aside | Not reported |
| Pricing type | FIRM FIXED PRICE |
| Obligations | $3.2M |
| Current contract value | $3.2M |
| Potential contract value / ceiling | $3.2M |
| Start date | Sep 24, 2013 |
| Current end date | Dec 31, 2025 |
| Potential end date | Dec 31, 2025 |
| Latest award activity | Sep 26, 2025 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 13 of 13 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Sep 26, 2025 | P00012 | $0 | EVALUATION OF THE PHARMACOKINETIC PROFILE, EFFECTS ON THE MECHANISMS OF CONTRACEPTIVE EFFICACY AND SAFETY OF MULTIPURPOSE PREVENTION TECHNOLOGIES PRODUCTS |
| Aug 14, 2024 | P00011 | $432.1K | EVALUATION OF THE PHARMACOKINETIC PROFILE, EFFECTS ON THE MECHANISMS OF CONTRACEPTIVE EFFICACY AND SAFETY OF MULTIPURPOSE PREVENTION TECHNOLOGIES PRODUCTS |
| Sep 1, 2023 | P00010 | $598.2K | EVALUATION OF THE PHARMACOKINETIC PROFILE, EFFECTS ON THE MECHANISMS OF CONTRACEPTIVE EFFICACY AND SAFETY OF MULTIPURPOSE PREVENTION TECHNOLOGIES PRODUCTS |
| Sep 27, 2022 | P00009 | $384.0K | EVALUATION OF THE PHARMACOKINETIC PROFILE, EFFECTS ON THE MECHANISMS OF CONTRACEPTIVE EFFICACY AND SAFETY OF MULTIPURPOSE PREVENTION TECHNOLOGIES PRODUCTS |
| Jul 2, 2021 | P00008 | $81.8K | EVALUATION OF THE PHARMACOKINETIC PROFILE, EFFECTS ON THE MECHANISMS OF CONTRACEPTIVE EFFICACY AND SAFETY OF MULTIPURPOSE PREVENTION TECHNOLOGIES PRODUCTS - TO ADD FUNDS IN THE AMOUNT OF $81,780.70 AND UPDATE FAR CLAUSES 52.204-24 AND 52.204-25. |
| Aug 12, 2020 | P00007 | $651.4K | EVALUATION OF THE PHARMACOKINETIC PROFILE, EFFECTS ON THE MECHANISMS OF CONTRACEPTIVE EFFICACY AND SAFETY OF MULTIPURPOSE PREVENTION TECHNOLOGIES PRODUCTS - TO ADD FUNDS IN THE AMOUNT OF $651,390 AND EXTEND THE PERIOD OF PERFORMANCE THROUGH SEPTEMBER |
| Aug 1, 2019 | P00006 | $55.7K | EVALUATION OF THE PHARMACOKINETIC PROFILE, EFFECTS ON THE MECHANISMS OF CONTRACEPTIVE EFFICACY AND SAFETY OF MULTIPURPOSE PREVENTION TECHNOLOGIES PRODUCTS - TO ADD FUNDS DUE TO A COST OVERRUN IN THE AMOUNT OF $55,685. |
| Apr 22, 2019 | P00005 | $0 | IGF::OT::IGF EVALUATION OF THE PHARMACOKINETIC PROFILE, EFFECTS ON THE MECHANISMS OF CONTRACEPTIVE EFFICACY AND SAFETY OF MULTIPURPOSE PREVENTION TECHNOLOGIES PRODUCTS |
| Mar 4, 2019 | P00004 | $6.0K | IGF::OT::IGF EVALUATION OF THE PHARMACOKINETIC PROFILE, EFFECTS ON THE MECHANISMS OF CONTRACEPTIVE EFFICACY AND SAFETY OF MULTIPURPOSE PREVENTION TECHNOLOGIES PRODUCTS |
| Jul 23, 2018 | 3 | $282.8K | IGF::OT::IGF EVALUATION OF THE PHARMACOKINETIC PROFILE, EFFECTS ON THE MECHANISMS OF CONTRACEPTIVE EFFICACY AND SAFETY OF MULTIPURPOSE PREVENTION TECHNOLOGIES PRODUCTS |
| Mar 30, 2018 | 2 | $9.1K | IGF::OT::IGF EVALUATION OF THE PHARMACOKINETIC PROFILE, EFFECTS ON THE MECHANISMS OF CONTRACEPTIVE EFFICACY AND SAFETY OF MULTIPURPOSE PREVENTION TECHNOLOGIES PRODUCTS |
| Sep 12, 2016 | 1 | $0 | IGF::OT::IGF EVALUATION OF THE PHARMACOKINETIC PROFILE, EFFECTS ON THE MECHANISMS OF CONTRACEPTIVE EFFICACY AND SAFETY OF MULTIPURPOSE PREVENTION TECHNOLOGIES PRODUCTS |
| Sep 24, 2013 | 0 | $669.8K | IGF::OT::IGF EVALUATION OF THE PHARMACOKINETIC PROFILE, EFFECTS ON THE MECHANISMS OF CONTRACEPTIVE EFFICACY AND SAFETY OF MULTIPURPOSE PREVENTION TECHNOLOGIES PRODUCTS |
Research next steps
- Confirm the ordering vehicle and your eligibility or a qualified teaming route.
- Review the award scope and buyer evidence before making a bid/no-bid decision.